Antibiotics are one of the most commonly used drugs in healthcare treatment. While they are used to prevent or treat bacterial infections, concern regarding their side effects and associated long-term health consequences is widely recognised.
Several studies have shown that repeated intake of antibiotics affects the resident microbiota which may pose negative effects on our bodies, including reduced species diversity, altered metabolic activity, antibiotic-associated diarrhea (AAD), recurrent Clostridioides difficile infections, and increases the risk of various diseases (e.g., diabetes, obesity, atopic dermatitis).
Another study also revealed that antibiotic exposure was associated with a reduction in both richness and diversity of microbiome in children 0-18 years. The use of antibiotics was associated with a reduced number of ‘beneficial’ gut bacteria such as Bifidobacteria and Lactobacilli that can produce short-chain fatty acids (SCFAs). SCFAs play a very important role in maintaining intestinal and metabolic health.
A recent study discovered that gut bacteria are critical to restoring gut health after antibiotic treatment. As it takes approximately six months to recover from the damage done by antibiotics, it is crucial to replenish your gut’s good bacteria with a healthy diet and probiotic supplements during and after a course of antibiotics. Since the gut microbiome is highly adaptable and responsive to a positive diet, one with a variety of fiber-rich whole foods (prebiotics) and a selection of probiotic supplements can speed up restoration of the gut microbiome.
G-NiiB ‘Immunity +’ is a unique microbiome immunity formula containing live freeze-dried ‘good’ bacteria with patented microencapsulation technology from Italy, and heat-resistant prebiotics to replenish beneficial microbes in the human gut. Using our proprietary database of over 10,000 subjects, big data analysis and machine learning algorithms, G-NiiB Immunity+ was formulated with an optimized 3+3 best ratio of live good bacteria and prebiotics to provide the BEST result and achieve our health goal.
G-NiiB has obtained exclusive patent* licensing from the Chinese University of Hong Kong. G-NiiB is a trademark of GenieBiome, a leading microbiome biotechnology start-up founded by professors from The Chinese University of Hong Kong.
Delivery in Singapore: https://bit.ly/3eXZ1h7
Delivery in Malaysia: https://bit.ly/3wZUGAl
The Uniqueness of G-NiiB Immunity+
- The first and only microbiome precision formula based on scientific data of COVID-19 patients.
- Immunity+ is clinically shown to be effective and safe in local novel virus patients.
- Researched and developed by The Chinese University of Hong Kong.
- Contains the 3+3 best ratio of live good bacteria and prebiotics based on the precise AI machine learning result
- Adopted patented microencapsulation technology from Italy ensures sufficient good live bacteria reach your intestine to deliver therapeutic actions and a long shelf-life.
Chng, K.R., Ghosh, T.S., Tan, Y.H. et al. Metagenome-wide association analysis identifies microbial determinants of post-antibiotic ecological recovery in the gut. Nat Ecol Evol 4, 1256–1267 (2020). https://doi.org/10.1038/s41559-020-1236-0
Lucy McDonnell, Alexander Gilkes, Mark Ashworth, Victoria Rowland, Timothy Hugh Harries, David Armstrong & Patrick White (2021) Association between antibiotics and gut microbiome dysbiosis in children: systematic review and meta-analysis, Gut Microbes, 13:1, https://doi.org/10.1080/19490976.2020.1870402
Ramirez, J., Guarner, F., Bustos Fernandez, L., Maruy, A., Sdepanian, V. L., & Cohen, H. (2020). Antibiotics as Major Disruptors of Gut Microbiota. Frontiers in cellular and infection microbiology, 10, 572912. https://doi.org/10.3389/fcimb.2020.572912
Canakis, A., Haroon, M., & Weber, H. C. (2020). Irritable bowel syndrome and gut microbiota. Current opinion in endocrinology, diabetes, and obesity, 27(1), 28–35. https://doi.org/10.1097/MED.0000000000000523
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008). The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS biology, 6(11), e280. https://doi.org/10.1371/journal.pbio.0060280